Novartis ends ALS program after phase 2 flop, adding to R&D woes September 16, 2026Posted inBiotechnology Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial. Post navigation Previous Post Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotechNext PostRed Light Supercharges Anti-Obesity Drug Precursor
